Braveheart Investment Group plc (AIM: BRH) provides the following update on Phasefocus and Paraytec, companies within the Group’s investment portfolio.
Braveheart Investment Group plc (AIM: BRH) provides the following update on Phasefocus and Paraytec, companies within the Group’s investment portfolio.
After being suspended pending its deal making since last year, San Leon (SLE), the independent oil and gas production, development and exploration company focused on Nigeria, announced that the suspension
Xtract Resources (XTR) report on three further drill holes completed in the area between Racecourse and Ascot on the Bushranger copper-gold porphyry exploration project.
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection includes Blencowe, Bidstack, Braveheart, Berkeley, Bigblu, Caracal, IG, Joules,
Braveheart Investment Group plc (AIM: BRH), provides the following update on its investment portfolio and strategy.
There was a reiteration of its current position in the wake of the Ukraine invasion from Eurasia Mining (EUA), the palladium, platinum, rhodium, iridium and gold producing company.
Zak Mir takes a charting perspective on some of the most followed London small caps. Today’s selection includes  Braveheart, Bluebird, Caerus, Cloudbreak, Evraz, Itaconix, Jangada, Kistos, Live, Okyo, Premier, Quetzal,
Zak Mir takes a charting look at some of the most followed small caps. Today’s selection includes Amur, Asiamet, African Pioneer, Braveheart, IDE, Nostrum, Petra, React, SkinBio, Scotgold, ValiRx, Xtract.
A busy week in the markets and international politics with events no doubt affecting markets., oil, in particular, could surge if any conflict erupts with Russia in Ukraine.
Braveheart Investment Group plc (AIM: BRH), is pleased to provide the following update on Paraytec, a company within the Group’s investment portfolio. Recent upgrades to the CX300 instrument indicate a
Halt the use of inaccurate Chinese lateral flow tests, with most already banned by the likes of the FDA.